Medical & Pharmacology Glossary

Plain-language definitions of 60 common terms found in drug monographs, FDA labels, and clinical literature.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

A

Adverse Reaction: An unwanted or harmful response to a medication taken at a normal dose. Adverse reactions range from mild (rash, nausea) to severe (organ damage, anaphylaxis) and are documented in a drug's FDA-approved labeling.
ANDA (Abbreviated New Drug Application): The FDA submission pathway for generic drugs. An ANDA demonstrates that a generic product is bioequivalent to a previously approved brand-name drug, without requiring new clinical efficacy trials.
AUC (Area Under the Curve): A pharmacokinetic measure of total drug exposure over time. AUC represents the total amount of drug absorbed into the bloodstream after a dose and is used to compare how much drug the body actually receives.

B

Bioavailability: The percentage of an administered drug dose that reaches the bloodstream in active form. Intravenous drugs have 100% bioavailability; oral drugs are lower because some drug is lost during absorption and first-pass metabolism in the liver.
Bioequivalence: A regulatory standard confirming that two formulations of the same drug (typically a generic and its brand-name counterpart) deliver the same amount of active ingredient into the bloodstream at the same rate. The FDA requires bioequivalence for generic drug approval.
Black Box Warning: The strongest safety warning the FDA requires on a drug's label, indicated by a bold black border. Black box warnings alert prescribers and patients to serious or life-threatening risks associated with the medication.
Branded Drug: A medication marketed under a proprietary trade name by the company that originally developed it. Brand-name drugs are protected by patents; when patents expire, generic versions may be approved.

C

Cmax (Maximum Concentration): The highest concentration of a drug measured in the blood after a dose is given. Cmax helps determine how quickly and intensely a drug acts and is a key pharmacokinetic parameter.
Contraindication: A condition or factor that makes a particular medication inadvisable or potentially dangerous for a patient. For example, a drug may be contraindicated in pregnancy or in patients with severe liver disease.
Controlled Substance: A drug regulated by the federal government under the Controlled Substances Act because of its potential for abuse or dependence. Controlled substances are classified into DEA Schedules I through V, with Schedule I having the highest abuse potential.
CYP2D6: A specific CYP450 liver enzyme that metabolizes roughly 25% of all prescription drugs, including many antidepressants, antipsychotics, and opioids. Genetic variations in CYP2D6 can make some people metabolize these drugs faster or slower than average.
CYP3A4: The most abundant CYP450 enzyme in the liver, responsible for metabolizing approximately 50% of all drugs. Many drug interactions occur because one medication inhibits or induces CYP3A4, affecting the levels of another drug.
CYP450 (Cytochrome P450): A family of liver enzymes responsible for metabolizing the majority of prescription drugs. When one drug affects a CYP450 enzyme, it can alter the blood levels of other drugs processed by that enzyme, causing interactions.

D

DEA Schedule: A classification system used by the U.S. Drug Enforcement Administration to categorize controlled substances by their medical use and potential for abuse. Schedule I drugs have no accepted medical use; Schedule V drugs have the lowest abuse potential among controlled substances.
Dose-Response Relationship: The relationship between the amount of drug administered and the magnitude of its effect. In general, higher doses produce greater effects up to a maximum, beyond which increasing the dose only increases toxicity without additional benefit.
Drug Formulary: A list of prescription drugs covered by a health insurance plan or pharmacy benefit manager. Drugs on the formulary are typically grouped into tiers, with lower tiers having lower out-of-pocket costs. Non-formulary drugs may not be covered or may require prior authorization.

E

Enteric-Coated: A special coating on a pill or capsule that prevents it from dissolving in the stomach, allowing it to pass intact into the small intestine before releasing the drug. This protects the stomach lining or protects acid-sensitive drugs from degradation.
Enzyme Inducer: A substance that increases the activity of a drug-metabolizing enzyme, causing other drugs processed by that enzyme to be broken down faster. This can reduce the effectiveness of those medications.
Enzyme Inhibitor: A substance that decreases the activity of a drug-metabolizing enzyme, causing other drugs processed by that enzyme to be broken down more slowly. This can increase blood levels and the risk of side effects for those medications.
Extended-Release (ER/XR): A drug formulation designed to release the active ingredient slowly over an extended period, allowing less frequent dosing (often once or twice daily instead of multiple times). Extended-release tablets should generally not be crushed or split.

F

FDA (Food and Drug Administration): The U.S. federal agency responsible for regulating and approving prescription drugs, over-the-counter medications, medical devices, and other health products. The FDA evaluates safety and efficacy data before allowing drugs to be marketed.
First-Pass Metabolism: The initial breakdown of an orally administered drug by the liver before it reaches the general circulation. First-pass metabolism can significantly reduce the amount of active drug that enters the bloodstream, which is why some drugs must be given by injection or other routes.

G

Generic Drug: A medication that contains the same active ingredient, dosage form, strength, and route of administration as a brand-name drug. Generics must meet FDA bioequivalence standards and are typically less expensive than their branded counterparts.

H

Half-Life: The time it takes for the concentration of a drug in the blood to decrease by half. Half-life determines how frequently a drug needs to be dosed and how long it takes to be cleared from the body.
Hepatotoxicity: Liver damage or injury caused by a medication. Some drugs carry a risk of hepatotoxicity that requires periodic liver function tests during treatment. Symptoms may include yellowing of the skin (jaundice), dark urine, and abdominal pain.

I

Immediate-Release (IR): A drug formulation that releases the full dose of active ingredient right after administration, without any mechanism to delay or prolong absorption. Immediate-release drugs typically reach peak blood levels faster but may require more frequent dosing.
Indication: The specific disease, condition, or symptom for which the FDA has approved a drug to be used. A drug may have one or several indications listed on its official label.

J

Jaundice (Drug-Induced): Yellowing of the skin and whites of the eyes caused by a buildup of bilirubin, which can occur when a medication damages the liver or blocks bile flow. Drug-induced jaundice is a serious sign that requires immediate medical attention and usually discontinuation of the causative drug.

K

Kinetics (Pharmacokinetics): The study of how the body absorbs, distributes, metabolizes, and excretes a drug over time. Pharmacokinetic properties determine how quickly a drug works, how long it lasts, and how frequently it needs to be dosed.

L

Loading Dose: An initial higher dose of a medication given to quickly achieve a therapeutic blood level, followed by smaller maintenance doses. Loading doses are used when it would take too long for regular dosing to build up to effective levels.

M

Maintenance Dose: The ongoing, regularly scheduled dose of a medication that keeps drug levels within the therapeutic range after the initial loading phase. Maintenance doses are what most patients take on a daily basis.
Medication Therapy Management (MTM): A comprehensive review of all medications a patient takes, performed by a pharmacist to optimize drug therapy, identify interactions, reduce side effects, and improve adherence. MTM is covered by Medicare Part D for qualifying beneficiaries.
Metabolite: A substance produced when the body breaks down (metabolizes) a drug. Some metabolites are inactive, while others are pharmacologically active and contribute to the drug's therapeutic effect or side effects. Prodrugs are inactive until converted to active metabolites.

N

Narrow Therapeutic Index (NTI): A characteristic of drugs where the difference between an effective dose and a toxic dose is very small. NTI drugs (such as warfarin, lithium, and digoxin) require careful dosing and frequent blood level monitoring to avoid toxicity.
NDA (New Drug Application): The formal submission to the FDA requesting approval to market a new drug. An NDA includes comprehensive data from preclinical and clinical studies demonstrating the drug's safety and efficacy.
Nephrotoxicity: Kidney damage or injury caused by a medication. Nephrotoxic drugs may require dose adjustments in patients with reduced kidney function, and kidney function may need to be monitored during treatment.

O

Off-Label Use: The prescribing of an FDA-approved drug for a condition, age group, or dosage not included in its official labeling. Off-label use is legal and common in medical practice, often supported by clinical evidence even though the FDA has not formally reviewed it for that purpose.
OTC (Over-the-Counter): Medications that can be purchased without a prescription. OTC drugs are considered safe enough for consumer self-selection and use when label directions are followed, though they can still cause side effects and interact with prescription medications.

P

P-Glycoprotein (P-gp): A transport protein found in the intestines, liver, kidneys, and brain that pumps drugs out of cells. P-gp affects how much of a drug is absorbed and distributed in the body; drugs that inhibit or induce P-gp can alter the levels of other medications.
Pharmacogenomics: The study of how a person's genetic makeup affects their response to drugs. Pharmacogenomic testing can identify patients who metabolize certain drugs faster or slower than average, helping doctors choose the right drug and dose for each individual.
Polypharmacy: The simultaneous use of multiple medications by a single patient, typically defined as taking five or more drugs. Polypharmacy increases the risk of drug interactions, adverse effects, medication errors, and reduced adherence, particularly in older adults.
Prior Authorization: A requirement from a health insurance plan that a prescriber must obtain approval before certain medications will be covered. Prior authorization is used to ensure medical necessity and may require documentation of the patient's condition and previous treatments.
Prodrug: A medication that is administered in an inactive (or less active) form and is converted to its active form inside the body through metabolism. Examples include codeine (converted to morphine) and enalapril (converted to enalaprilat).

Q

QT Prolongation: An abnormal lengthening of the QT interval on an electrocardiogram (ECG), which can increase the risk of dangerous irregular heart rhythms (arrhythmias). Some medications carry warnings about QT prolongation, especially when combined with other QT-prolonging drugs.

R

Rebound Effect: A worsening of symptoms that occurs when a medication is stopped abruptly, often with symptoms becoming worse than they were before treatment began. Rebound effects are common with certain nasal decongestants, proton pump inhibitors, and some blood pressure medications.
REMS (Risk Evaluation and Mitigation Strategy): An FDA-required safety program for certain medications with serious safety concerns. REMS may include medication guides, communication plans, restricted distribution systems, or mandatory patient registries. Examples include iPLEDGE for isotretinoin and Clozapine REMS.
Rhabdomyolysis: A serious condition involving the breakdown of muscle tissue, which releases harmful proteins into the bloodstream that can damage the kidneys. Certain medications (notably statins in rare cases) can trigger rhabdomyolysis, with symptoms including severe muscle pain, weakness, and dark urine.

S

Serotonin Syndrome: A potentially life-threatening condition caused by excessive serotonin activity in the nervous system, usually from combining two or more serotonergic drugs. Symptoms include agitation, rapid heart rate, high blood pressure, muscle rigidity, and elevated body temperature.
Steady State: The point at which the rate of drug entering the body equals the rate of drug being eliminated, resulting in a stable blood level. Most drugs reach steady state after 4-5 half-lives of consistent dosing. Dose adjustments should generally be evaluated at steady state.
Stevens-Johnson Syndrome (SJS): A rare but severe allergic reaction to medication that causes painful blistering of the skin and mucous membranes. SJS is a medical emergency that requires immediate hospitalization and discontinuation of the causative drug.
Substrate: A drug or substance that is metabolized by a specific enzyme. For example, a drug that is a CYP3A4 substrate is broken down by the CYP3A4 enzyme, and its blood levels can change if another drug inhibits or induces that enzyme.

T

Taper: A gradual, stepwise reduction in a drug's dose over days or weeks to avoid withdrawal symptoms or rebound effects. Tapering is commonly required for medications like corticosteroids, benzodiazepines, and certain antidepressants.
Teratogenic: Capable of causing birth defects when taken during pregnancy. Teratogenic drugs are classified with pregnancy warnings and may be absolutely contraindicated or require special risk management programs (such as iPLEDGE for isotretinoin).
Therapeutic Index: The ratio between the dose of a drug that causes a toxic effect and the dose that produces the desired therapeutic effect. A wide therapeutic index means there is a large margin of safety; a narrow one means small dose changes can cause toxicity.
Titration: The process of gradually adjusting a drug dose upward or downward to find the lowest effective dose with acceptable side effects. Titration is common with medications for blood pressure, pain, and psychiatric conditions.
Trough Level: The lowest concentration of a drug in the blood, measured just before the next scheduled dose. Trough levels are used to monitor drugs with narrow therapeutic indices (such as vancomycin and aminoglycosides) to ensure adequate dosing without toxicity.

U

UGT (UDP-Glucuronosyltransferase): A family of liver enzymes involved in Phase II drug metabolism that attach glucuronic acid to drugs, making them more water-soluble for excretion. UGT enzymes metabolize many common drugs including lamotrigine, acetaminophen, and morphine.

V

Volume of Distribution (Vd): A pharmacokinetic parameter that describes how extensively a drug distributes throughout the body's tissues relative to blood. A large volume of distribution means the drug concentrates in tissues rather than staying in the bloodstream.

W

Washout Period: The time required after stopping a medication before starting a new one, to allow the first drug to be fully eliminated from the body. Washout periods prevent dangerous interactions between the outgoing and incoming medications.

X

Xerostomia: The medical term for dry mouth, a common side effect of many medications including anticholinergics, antidepressants, antihistamines, and antihypertensives. Chronic xerostomia increases the risk of dental cavities, gum disease, and oral infections.

Related Resources

Drugs A–Z — Browse all drug monographs
Editorial Policy — How we create and review content